Temple Faculty Physicians is experiencing technical issues with phone lines. If you are experiencing an emergency, please visit your nearest emergency room. If you would like to schedule an appointment with your provider or have general questions or requests, please contact us by using myTempleHealth.

myTempleHealth
800-TEMPLE-MED Schedule Appointment
SEARCH TEMPLE HEALTH

Study of INBRX-101 Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema (ELEVAATE)

view all Clinical Trials

Overview

This is a Phase 2, Double-Blind, Randomized, Active-Control, Parallel Group Study to Assess the Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of INBRX-101 Compared to Plasma-Derived Alpha1-Proteinase Inhibitor (A1PI) Augmentation Therapy in Adults With Alpha-1 Antitrypsin Deficiency (AATD) Emphysema.

Clinical Trial Information

Protocol

TIRB# 31330

Phase

2

Condition(s)

Emphysema, Alpha-1 Antitrypsin Deficiency, Chronic Obstructive Pulmonary Disease (COPD)

Investigator

Wissam Chatila, MD

Coordinator

Sara Khademolhosseini

Visit clinicaltrials.gov for full description.

Contact

For more information about this trial or to inquire about eligibility, email [email protected] or call 215-707-1359.

Full Title

Phase 2, Double-Blind, Randomized, Active-Control, Parallel Group Study to Assess the Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of INBRX-101 Compared to Plasma-Derived Alpha1-Proteinase Inhibitor (A1PI) Augmentation Therapy in Adults With Alpha-1 Antitrypsin Deficiency (AATD) Emphysema

Related Clinical Trials

Hyperpolarized Xenon Functional Lung Imaging in COPD Patients Undergoing Targeted Lung Denervation

TIRB# 29791
  • Conditions: Chronic Obstructive Pulmonary Disease (COPD)
  • Investigator: Gerard Criner, MD
  • Coordinator: David Miller
View Details

A Phase 2a Randomized, Doubled-Blind, Placebo-Controlled Trial to Evaluate Safety, Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Relationships of RLS-0071 in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

  • Conditions: Chronic Obstructive Pulmonary Disease (COPD)
  • Investigator: Gerard Criner, MD
  • Coordinator: Dave Miller
View Details

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-1)

TIRB# 30801
  • Conditions: Chronic Obstructive Pulmonary Disease (COPD)
  • Investigator: Gerard Criner, MD
  • Coordinator: Debasree Sana Boral
View Details